A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase to Counter Nonalcoholic Steatohepatitis

Journal of Medicinal Chemistry

Volumn 60, Issue 18, 2017, Pages 7703-7724

  Schmidt, Jurema ^a   Rotter, Marco ^a   Weiser, Tim ^a   Wittmann, Sandra ^a   Weizel, Lilia ^a   Kaiser, Astrid ^a   Heering, Jan ^b   Goebel, Tamara ^a   Angioni, Carlo ^a   Wurglics, Mario ^a   Paulke, Alexander ^a   Geisslinger, Gerd ^a   Kahnt, Astrid ^a   Steinhilber, Dieter ^a   Proschak, Ewgenij ^a   Merk, Daniel ^a  

^a GOETHE UNIVERSITY   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHENYL DERIVATIVE; CARBOXYLIC ACID; EPOXIDE HYDROLASE; FARNESOID X RECEPTOR; GSK 2188931B; HYDROLASE INHIBITOR; LIVER PROTECTIVE AGENT; SULFONAMIDE; ANTIINFLAMMATORY AGENT; CELL RECEPTOR; ENZYME INHIBITOR; FARNESOID X-ACTIVATED RECEPTOR;

ARTICLE; ATOM; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VITRO STUDY; LIVER PROTECTION; MOLECULAR DOCKING; NONALCOHOLIC FATTY LIVER; PARTIAL AGONISM; PHARMACOPHORE; PROTEIN TARGETING; REACTION OPTIMIZATION; RECEPTOR BINDING; REPORTER GENE; STRUCTURE ACTIVITY RELATION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; HELA CELL LINE; HEP-G2 CELL LINE; LIVER; MALE; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG DISCOVERY; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HELA CELLS; HEP G2 CELLS; HUMANS; LIVER; MALE; MICE, INBRED C57BL; MOLECULAR DOCKING SIMULATION; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85030241468     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.7b00398     Document Type: Article

References (56)

1. Rinella, M. E. Nonalcoholic Fatty Liver Disease: A Systematic Review JAMA 2015, 313 (22) 2263-2273 10.1001/jama.2015.5370
2. Gawrieh, S.; Chalasani, N. Pharmacotherapy for Nonalcoholic Fatty Liver Disease Semin. Liver Dis. 2015, 35 (3) 338-348 10.1055/s-0035-1562951
3. Chalasani, N.; Younossi, Z.; Lavine, J. E.; Diehl, A. M.; Brunt, E. M.; Cusi, K.; Charlton, M.; Sanyal, A. J. The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association Hepatology 2012, 55 (6) 2005-2023 10.1002/hep.25762
4. Arab, J. P.; Karpen, S. J.; Dawson, P. A.; Arrese, M.; Trauner, M. Bile Acids and Nonalcoholic Fatty Liver Disease: Molecular Insights and Therapeutic Perspectives Hepatology 2017, 65 (1) 350-362 10.1002/hep.28709
5. Adorini, L.; Pruzanski, M.; Shapiro, D. Farnesoid X Receptor Targeting to Treat Nonalcoholic Steatohepatitis Drug Discovery Today 2012, 17 (17-18) 988-997 10.1016/j.drudis.2012.05.012
6. Neuschwander-Tetri, B. A.; Loomba, R.; Sanyal, A. J.; Lavine, J. E.; Van Natta, M. L.; Abdelmalek, M. F.; Chalasani, N.; Dasarathy, S.; Diehl, A. M.; Hameed, B.; Kowdley, K. V.; McCullough, A.; Terrault, N.; Clark, J. M.; Tonascia, J.; Brunt, E. M.; Kleiner, D. E.; Doo, E. Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-Cirrhotic, Non-Alcoholic Steatohepatitis (FLINT): A Multicentre, Randomised, Placebo-Controlled Trial Lancet 2015, 385 (9972) 956-965 10.1016/S0140-6736(14)61933-4
7. Makishima, M.; Okamoto, A. Y.; Repa, J. J.; Tu, H.; Learned, R. M.; Luk, A.; Hull, M. V.; Lustig, K. D.; Mangelsdorf, D. J.; Shan, B. Identification of a Nuclear Receptor for Bile Acids Science 1999, 284 (5418) 1362-1365 10.1126/science.284.5418.1362
8. Parks, D. J.; Blanchard, S. G.; Bledsoe, R. K.; Chandra, G.; Consler, T. G.; Kliewer, S. A.; Stimmel, J. B.; Willson, T. M.; Zavacki, A. M.; Moore, D. D.; Lehmann, J. M. Bile Acids: Natural Ligands for an Orphan Nuclear Receptor Science 1999, 284 (5418) 1365-1368 10.1126/science.284.5418.1365
9. Wang, H.; Chen, J.; Hollister, K.; Sowers, L. C.; Forman, B. M. Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR Mol. Cell 1999, 3 (5) 543-553 10.1016/S1097-2765(00)80348-2
10. Gadaleta, R. M.; Cariello, M.; Sabbà, C.; Moschetta, A. Tissue-Specific Actions of FXR in Metabolism and Cancer Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2015, 1851, 30-39 10.1016/j.bbalip.2014.08.005
11. Pellicciari, R.; Costantino, G.; Fiorucci, S. Farnesoid X Receptor: From Structure to Potential Clinical Applications J. Med. Chem. 2005, 48 (17) 5383-5403 10.1021/jm0582221
12. Mudaliar, S.; Henry, R. R.; Sanyal, A. J.; Morrow, L.; Marschall, H. U.; Kipnes, M.; Adorini, L.; Sciacca, C. I.; Clopton, P.; Castelloe, E.; Dillon, P.; Pruzanski, M.; Shapiro, D. Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease Gastroenterology 2013, 145 (3) 574-582 10.1053/j.gastro.2013.05.042
13. Ali, A. H.; Carey, E. J.; Lindor, K. D. Recent Advances in the Development of Farnesoid X Receptor Agonists Ann. Transl. Med. 2015, 3 (1) 5 10.3978/j.issn.2305-5839.2014
14. Merk, D.; Gabler, M.; Gomez, R. C.; Flesch, D.; Hanke, T.; Kaiser, A.; Lamers, C.; Werz, O.; Schneider, G.; Schubert-Zsilavecz, M. Anthranilic Acid Derivatives as Novel Ligands for Farnesoid X Receptor (FXR) Bioorg. Med. Chem. 2014, 22 (8) 2447-2460 10.1016/j.bmc.2014.02.053
15. Merk, D.; Lamers, C.; Ahmad, K.; Gomez, R. C.; Schneider, G.; Steinhilber, D.; Schubert-zsilavecz, M. Extending the Structure-Activity Relationship of Anthranilic Acid Derivatives As Farnesoid X Receptor Modulators: Development of a Highly Potent Partial Farnesoid X Receptor Agonist J. Med. Chem. 2014, 57 (19) 8035-8055 10.1021/jm500937v
16. Merk, D.; Steinhilber, D.; Schubert-Zsilavecz, M. Medicinal Chemistry of Farnesoid X Receptor Ligands: From Agonists and Antagonists to Modulators Future Med. Chem. 2012, 4 (8) 1015-1036 10.4155/fmc.12.47
17. Shen, H. C.; Hammock, B. D. Discovery of Inhibitors of Soluble Epoxide Hydrolase: A Target with Multiple Potential Therapeutic Indications J. Med. Chem. 2012, 55 (5) 1789-1808 10.1021/jm201468j
18. Imig, J. D. Epoxides and Soluble Epoxide Hydrolase in Cardiovascular Physiology Physiol. Rev. 2012, 92 (1) 101-130 10.1152/physrev.00021.2011
19. Huang, H.; Weng, J.; Wang, M.-H. EETs/sEH in Diabetes and Obesity-Induced Cardiovascular Diseases Prostaglandins Other Lipid Mediators 2016, 125, 80-89 10.1016/j.prostaglandins.2016.05.004
20. Harris, T. R.; Hammock, B. D. Soluble Epoxide Hydrolase: Gene Structure, Expression and Deletion Gene 2013, 526 (2) 61-74 10.1016/j.gene.2013.05.008
21. Liu, Y.; Dang, H.; Li, D.; Pang, W.; Hammock, B. D.; Zhu, Y. Inhibition of Soluble Epoxide Hydrolase Attenuates High-Fat-Diet-Induced Hepatic Steatosis by Reduced Systemic Inflammatory Status in Mice PLoS One 2012, 7 (6) e39165 10.1371/journal.pone.0039165
22. Schuck, R. N.; Zha, W.; Edin, M. L.; Gruzdev, A.; Vendrov, K. C.; Miller, T. M.; Xu, Z.; Lih, F. B.; DeGraff, L. M.; Tomer, K. B.; Jones, H. M.; Makowski, L.; Huang, L.; Poloyac, S. M.; Zeldin, D. C.; Lee, C. R. The Cytochrome P450 Epoxygenase Pathway Regulates the Hepatic Inflammatory Response in Fatty Liver Disease PLoS One 2014, 9 (10) e110162 10.1371/journal.pone.0110162
23. Sanyal, A. J. Novel Therapeutic Targets for Steatohepatitis Clin. Res. Hepatol. Gastroenterol. 2015, 39 (Suppl. 1) S46-S50 10.1016/j.clinre.2015.05.012
24. Milic, S.; Mikolasevic, I.; Krznaric-Zrnic, I.; Stanic, M.; Poropat, G.; Stimac, D.; Vlahovic-Palcevski, V.; Orlic, L. Nonalcoholic Steatohepatitis: Emerging Targeted Therapies to Optimize Treatment Options Drug Des., Dev. Ther. 2015, 9, 4835-4845 10.2147/DDDT.S64877
25. Morphy, R.; Rankovic, Z. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm J. Med. Chem. 2005, 48 (21) 6523-6543 10.1021/jm058225d
26. Morphy, R.; Rankovic, Z. Designing Multiple Ligands-Medicinal Chemistry Strategies and Challenges Curr. Pharm. Des. 2009, 15 (6) 587-600 10.2174/138161209787315594
27. Bansal, Y.; Silakari, O. Multifunctional Compounds: Smart Molecules for Multifactorial Diseases Eur. J. Med. Chem. 2014, 76, 31-42 10.1016/j.ejmech.2014.01.060
28. Peters, J.-U. Polypharmacology-Foe or Friend? J. Med. Chem. 2013, 56 (22) 8955-8971 10.1021/jm400856t
29. Merk, D.; Lamers, C.; Weber, J.; Flesch, D.; Gabler, M.; Proschak, E.; Schubert-Zsilavecz, M. Anthranilic Acid Derivatives as Nuclear Receptor modulators-Development of Novel PPAR Selective and Dual PPAR/FXR Ligands Bioorg. Med. Chem. 2015, 23 (3) 499-514 10.1016/j.bmc.2014.12.013
30. Lamers, C.; Merk, D.; Gabler, M.; Flesch, D.; Kaiser, A.; Schubert-Zsilavecz, M. SAR Studies on FXR Modulators Led to the Discovery of the First Combined FXR antagonistic/TGR5 Agonistic Compound Future Med. Chem. 2016, 8 (2) 133-148 10.4155/fmc.15.178
31. Flesch, D.; Gabler, M.; Lill, A.; Gomez, R. C.; Steri, R.; Schneider, G.; Stark, H.; Schubert-Zsilavecz, M.; Merk, D. Fragmentation of GW4064 Led to a Highly Potent Partial Farnesoid X Receptor Agonist with Improved Drug-like Properties Bioorg. Med. Chem. 2015, 23 (13) 3490-3498 10.1016/j.bmc.2015.04.035
32. Gomez, G. A.; Morisseau, C.; Hammock, B. D.; Christianson, D. W. Structure of Human Epoxide Hydrolase Reveals Mechanistic Inferences on Bifunctional Catalysis in Epoxide and Phosphate Ester Hydrolysis Biochemistry 2004, 43 (16) 4716-4723 10.1021/bi036189j
33. Kompa, A. R.; Wang, B. H.; Xu, G.; Zhang, Y.; Ho, P.-Y.; Eisennagel, S.; Thalji, R. K.; Marino, J. P.; Kelly, D. J.; Behm, D. J.; Krum, H. Soluble Epoxide Hydrolase Inhibition Exerts Beneficial Anti-Remodeling Actions Post-Myocardial Infarction Int. J. Cardiol. 2013, 167 (1) 210-219 10.1016/j.ijcard.2011.12.062
34. Maloney, P. R.; Parks, D. J.; Haffner, C. D.; Fivush, a. M.; Chandra, G.; Plunket, K. D.; Creech, K. L.; Moore, L. B.; Wilson, J. G.; Lewis, M. C.; Jones, S. a.; Willson, T. M. Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR J. Med. Chem. 2000, 43 (16) 2971-2974 10.1021/jm0002127
35. Morisseau, C.; Goodrow, M. H.; Newman, J. W.; Wheelock, C. E.; Dowdy, D. L.; Hammock, B. D. Structural Refinement of Inhibitors of Urea-Based Soluble Epoxide Hydrolases Biochem. Pharmacol. 2002, 63 (9) 1599-1608 10.1016/S0006-2952(02)00952-8
36. Jones, P. D.; Wolf, N. M.; Morisseau, C.; Whetstone, P.; Hock, B.; Hammock, B. D. Fluorescent Substrates for Soluble Epoxide Hydrolase and Application to Inhibition Studies Anal. Biochem. 2005, 343 (1) 66-75 10.1016/j.ab.2005.03.041
37. Costantino, G.; Entrena-Guadix, A.; Macchiarulo, A.; Gioiello, A.; Pellicciari, R. Molecular Dynamics Simulation of the Ligand Binding Domain of Farnesoid X Receptor. Insights into Helix-12 Stability and Coactivator Peptide Stabilization in Response to Agonist Binding J. Med. Chem. 2005, 48 (9) 3251-3259 10.1021/jm049182o
38. Ratziu, V.; Harrison, S. A.; Francque, S.; Bedossa, P.; Lehert, P.; Serfaty, L.; Romero-Gomez, M.; Boursier, J.; Abdelmalek, M.; Caldwell, S.; Drenth, J.; Anstee, Q. M.; Hum, D.; Hanf, R.; Roudot, A.; Megnien, S.; Staels, B.; Sanyal, A.; Mathurin, P.; Gournay, J.; Nguyen-Khac, E.; De Ledinghen, V.; Larrey, D.; Tran, A.; Bourliere, M.; Maynard-Muet, M.; Asselah, T.; Henrion, J.; Nevens, F.; Cassiman, D.; Geerts, A.; Moreno, C.; Beuers, U. H.; Galle, P. R.; Spengler, U.; Bugianesi, E.; Craxi, A.; Angelico, M.; Fargion, S.; Voiculescu, M.; Gheorghe, L.; Preotescu, L.; Caballeria, J.; Andrade, R. J.; Crespo, J.; Callera, J. L.; Ala, A.; Aithal, G.; Abouda, G.; Luketic, V.; Huang, M. A.; Gordon, S.; Pockros, P.; Poordad, F.; Shores, N.; Moehlen, M. W.; Bambha, K.; Clark, V.; Satapathy, S.; Parekh, S.; Reddy, R. K.; Sheikh, M. Y.; Szabo, G.; Vierling, J.; Foster, T.; Umpierrez, G.; Chang, C.; Box, T.; Gallegos-Orozco, J. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and-δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening Gastroenterology 2016, 150 (5) 1147-1159 10.1053/j.gastro.2016.01.038
39. Schuck, R. N.; Zha, W.; Edin, M. L.; Gruzdev, A.; Vendrov, K. C.; Miller, T. M.; Xu, Z.; Lih, F. B.; DeGraff, L. M.; Tomer, K. B.; Jones, H. M.; Makowski, L.; Huang, L.; Poloyac, S. M.; Zeldin, D. C.; Lee, C. R. The Cytochrome P450 Epoxygenase Pathway Regulates the Hepatic Inflammatory Response in Fatty Liver Disease PLoS One 2014, 9 (10) e110162 10.1371/journal.pone.0110162
40. Alisi, A.; Ceccarelli, S.; Panera, N.; Prono, F.; Petrini, S.; De Stefanis, C.; Pezzullo, M.; Tozzi, A.; Villani, A.; Bedogni, G.; Nobili, V. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease PLoS One 2013, 8 (6) e67160 10.1371/journal.pone.0067160
41. Lamers, C.; Schubert-Zsilavecz, M.; Merk, D. Therapeutic Modulators of Peroxisome Proliferator-Activated Receptors (PPAR): A Patent Review (2008-present) Expert Opin. Ther. Pat. 2012, 22 (7) 803-841 10.1517/13543776.2012.699042
42. Savkur, R. S.; Bramlett, K. S.; Michael, L. F.; Burris, T. P. Regulation of Pyruvate Dehydrogenase Kinase Expression by the Farnesoid X Receptor Biochem. Biophys. Res. Commun. 2005, 329 (1) 391-396 10.1016/j.bbrc.2005.01.141
43. Wang, G.; Bonkovsky, H. L.; de Lemos, A.; Burczynski, F. J. Recent Insights into the Biological Functions of Liver Fatty Acid Binding Protein 1 J. Lipid Res. 2015, 56 (12) 2238-2247 10.1194/jlr.R056705
44. Dong, L.; Zhou, Y.; Zhu, Z.-Q.; Liu, T.; Duan, J.-X.; Zhang, J.; Li, P.; Hammcok, B. D.; Guan, C.-X. Soluble Epoxide Hydrolase Inhibitor Suppresses the Expression of Triggering Receptor Expressed on Myeloid Cells-1 by Inhibiting NF-kB Activation in Murine Macrophage Inflammation 2017, 40 (1) 13-20 10.1007/s10753-016-0448-6
45. Zhou, Y.; Liu, T.; Duan, J.-X.; Li, P.; Sun, G.-Y.; Liu, Y.-P.; Zhang, J.; Dong, L.; Lee, K. S. S.; Hammock, B. D.; Jiang, J.-X.; Guan, C.-X. Soluble Epoxide Hydrolase Inhibitor Attenuates Lipopolysaccharide-Induced Acute Lung Injury and Improves Survival in Mice Shock 2017, 47 (5) 638-645 10.1097/SHK.0000000000000767
46. Trauner, M.; Boyer, J. L. Bile Salt Transporters: Molecular Characterization, Function, and Regulation Physiol. Rev. 2003, 83 (2) 633-671 10.1152/physrev.00027.2002
47. Soroka, C. J.; Boyer, J. L. Biosynthesis and Trafficking of the Bile Salt Export Pump, BSEP: Therapeutic Implications of BSEP Mutations Mol. Aspects Med. 2014, 37, 3-14 10.1016/j.mam.2013.05.001
48. Schmidt, J.; Klingler, F.-M.; Proschak, E.; Steinhilber, D.; Schubert-Zsilavecz, M.; Merk, D. NSAIDs Ibuprofen, Indometacin, and Diclofenac Do Not Interact with Farnesoid X Receptor Sci. Rep. 2015, 5, 14782 10.1038/srep14782
49. Steri, R.; Achenbach, J.; Steinhilber, D.; Schubert-Zsilavecz, M.; Proschak, E. Investigation of Imatinib and Other Approved Drugs as Starting Points for Antidiabetic Drug Discovery with FXR Modulating Activity Biochem. Pharmacol. 2012, 83 (12) 1674-1681 10.1016/j.bcp.2012.02.027
50. Ananthanarayanan, M.; Balasubramanian, N.; Makishima, M.; Mangelsdorf, D. J.; Suchy, F. J. Human Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor/bile Acid Receptor J. Biol. Chem. 2001, 276 (31) 28857-28865 10.1074/jbc.M011610200
51. Seuter, S.; Väisänen, S.; Rådmark, O.; Carlberg, C.; Steinhilber, D. Functional Characterization of Vitamin D Responding Regions in the Human 5-Lipoxygenase Gene Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2007, 1771 (7) 864-872 10.1016/j.bbalip.2007.04.007
52. Klingler, F.-M.; Wolf, M.; Wittmann, S.; Gribbon, P.; Proschak, E. Bacterial Expression and HTS Assessment of Soluble Epoxide Hydrolase Phosphatase J. Biomol. Screening 2016, 21 (7) 689-694 10.1177/1087057116637609
53. Blöcher, R.; Lamers, C.; Wittmann, S. K.; Merk, D.; Hartmann, M.; Weizel, L.; Diehl, O.; Brüggerhoff, A.; Boß, M.; Kaiser, A.; Schader, T.; Göbel, T.; Grundmann, M.; Angioni, C.; Heering, J.; Geisslinger, G.; Wurglics, M.; Kostenis, E.; Brüne, B.; Steinhilber, D.; Schubert-Zsilavecz, M.; Kahnt, A. S.; Proschak, E. N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/peroxisome Proliferator-Activated Receptor γ Modulators J. Med. Chem. 2016, 59 (1) 61-81 10.1021/acs.jmedchem.5b01239
54. Rau, O.; Wurglics, M.; Paulke, A.; Zitzkowski, J.; Meindl, N.; Bock, A.; Dingermann, T.; Abdel-Tawab, M.; Schubert-Zsilavecz, M. Carnosic Acid and Carnosol, Phenolic Diterpene Compounds of the Labiate Herbs Rosemary and Sage, Are Activators of the Human Peroxisome Proliferator-Activated Receptor Gamma Planta Med. 2006, 72 (10) 881-887 10.1055/s-2006-946680
55. Flesch, D.; Cheung, S.-Y.; Schmidt, J.; Gabler, M.; Heitel, P.; Kramer, J. S.; Kaiser, A.; Hartmann, M.; Lindner, M.; Lüddens-Dämgen, K.; Heering, J.; Lamers, C.; Lüddens, H.; Wurglics, M.; Proschak, E.; Schubert-Zsilavecz, M.; Merk, D. Nonacidic Farnesoid X Receptor Modulators J. Med. Chem. 2017, 60, 7199-7205 10.1021/acs.jmedchem.7b00903
56. Zha, W.; Edin, M. L.; Vendrov, K. C.; Schuck, R. N.; Lih, F. B.; Jat, J. L.; Bradbury, J. A.; DeGraff, L. M.; Hua, K.; Tomer, K. B.; Falck, J. R.; Zeldin, D. C.; Lee, C. R. Functional Characterization of Cytochrome P450-Derived Epoxyeicosatrienoic Acids in Adipogenesis and Obesity J. Lipid Res. 2014, 55 (10) 2124-2136 10.1194/jlr.M053199